Study of AIR-001 for adults with alpha-1 antitrypsin deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed Pi*ZZ genotype (a specific genetic type causing alpha-1 antitrypsin deficiency) and low levels of the protective AAT protein in your blood.
- You must not have used AAT augmentation therapy (infusions) in the last month and agree not to use it during the study.
- You cannot have smoked or vaped for at least 6 months.
- Your lung function (FEV1) must be at least 40% of what is expected for your age and height.
- You must not have severe liver scarring or other serious health conditions like uncontrolled heart disease or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
This study tests a one-time gene therapy called BEAM-302 that aims to fix the faulty gene causing alpha-1 antitrypsin deficiency (AATD), a condition that damages the lungs and liver. The goal is to improve AAT levels and slow or stop disease progression.
This trial tests a gene therapy for people with alpha-1 antitrypsin deficiency who have mild to moderate lung disease. The aim is to see if the treatment can improve lung health and is safe.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
This study collects health information from people who have alpha-1 antitrypsin deficiency. It may help doctors better understand the condition and improve care over time.
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.